21406 Federal Register / Vol. 66, No. 83 / Monday, April 30, 2001 / Notices

DHHS Reference Nos. E–145–99/0 and

E–009–01/0

Licensing Contact: Norbert Pontzer; 301/

496–7736, ext. 284; e-mail:

pontzern@od.nih.gov

Nestin is an intermediate filament

protein first described in early

embryonic neuroepithelial stem cells.

Although not found in most cells of the

mature CNS, nestin is the predominant

marker used to detect the small

population of undifferentiated cells. The

presence of nestin identifies stem,

progenitor and some tumor cells in the

CNS, and also labels areas of reactive

gliosis in the CNS. Available methods to

detect nestin use antibodies generated

against rat nestin protein. Since rat and

human nestin have only about fifty

percent sequence homology, these

antibodies may not be optimal for

detecting nestin in human cells.

NIH scientists used a novel human

nestin immunogen to generate

polyclonal and monoclonal antibodies

that bind with high affinity and

specificity to human nestin. The

immunogen was expressed from a 450

base-pair segment of human nestin

mRNA, which has 11 nucleotide

differences from previously published

human nestin. These antibodies

increase the specificity to accurately

detect human nestin in all stages of

brain development and will increase our

understanding of glial differentiation. In

addition, this technology may be useful

for detecting glioblastomas or other

early stage neuroectodermal tumors and

for following transplanted stem cells.

Dated: April 20, 2001.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer,

National Institutes of Health.

[FR Doc. 01–10580 Filed 4–27–01; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Statement of Organization, Functions,

and Delegations of Authority

Part N, National Institutes of Health,

of the Statement of Organization,

Functions, and Delegations of Authority

for the Department of Health and

Human Services (40 FR 22859), May 27,

1975, as amended most recently at 66

FR 6617, January 22, 2001, and

redesignated from Part HN as Part N at

60 FR 56605, November 9, 1995), is

amended as set forth below to

reorganize the Office of the Director,

NIH, as follows: (1) Abolish the Office

of Bioengineering, Bioimaging, and

Bioinformatics.

Section N–B, Organization and

Functions, under the heading Office of

the Director (NA, formerly HNA), is

amended as follows:

(1) Immediately following the

statement for the Executive Office (NAR,

formerly HNAR), the title and functional

statement of the Office of

Bioengineering, Bioimaging, and

Bioinformatics (NAC, formerly HNAC)

as deleted in their entirety.

DELEGATIONS OF AUTHORITY

STATEMENT: All delegations and

redelegations of authority to officers and

employees of NIH which were in effect

immediately prior to the effective date

of this reorganization and are consistent

with this reorganization shall continue

in effect, pending further redelegation.

Dated: March 6, 2001.

Ruth L. Kirschstein,

Acting Director, National Institutes of Health.

[FR Doc. 01–10581 Filed 4–27–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive

License: Bacteriophage Having

Multiple Host Range

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance

with 35 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(i), that the National

Institutes of Health (NIH), Department

of Health and Human Services, is

contemplating the grant of a an

exclusive license to practice the

invention embodied in: United States

Patent Application 60/220,987 entitled

‘‘Bacteriophage Having Multiple Host

Range’’ filed on July 25, 2000, to

BioPhage, Inc., having a place of

business in Montreal, Quebec. The

patent rights in this invention have been

assigned to the United States of

America.

DATES: Only written comments and/or

application for a license which are

received by the NIH Office of

Technology Transfer on or before June

29, 2001 will be considered.

ADDRESSES: Requests for a copy of the

patent applications, inquiries,

comments and other materials relating

to the contemplated license should be

directed to: Peter Soukas, Office of

Technology Transfer, National Institutes

of Health, 6011 Executive Boulevard,

Suite 325, Rockville, MD 20852–3804;

Email: ps193c@nih.gov; Telephone:

(301) 496–7056, ext. 268; Facsimile:

(301) 402–0220.

SUPPLEMENTARY INFORMATION: This

invention concerns bacteriophage with

specificity to more than one bacterial

species and the ability to make such

bacteriophages. The specificity is

broadened and/or changed by genetic

engineering of the phage tail proteins.

The phage can be used to kill

pathogenic bacteria in both animals and

humans. The use of phages as

antibacterials may be one answer to the

problem of antibiotic resistant bacteria.

The prospective exclusive license will

be royalty bearing and will comply with

the terms and conditions of 35 U.S.C.

209 and 37 CFR 404.7. The prospective

exclusive license may be granted unless,

within 60 days from the date of this

published Notice, NIH receives written

evidence and argument that establishes

that the grant of the license would not

be consistent with the requirements of

35 U.S.C. 209 and 37 CFR 404.7.

The field of use may be limited to

prophylaxis and/or treatment of

bacterial infections in non-human

animals and treatment and/or

prophylaxis of antibiotic resistant

bacteria in humans.

Properly filed competing applications

for a license filed in response to this

notice will be treated as objections to

the contemplated license. Comments

and objections submitted in response to

this notice will not be made available

for public inspection, and, to the extent

permitted by law, will not be released

under the Freedom of Information Act,

5 U.S.C. 552.

Dated: April 20, 2001.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer.

[FR Doc. 01–10576 Filed 4–27–01; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive

License: MHC Class II Restricted

Melanoma Antigens and Their Use in

Therapeutic Methods

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice

SUMMARY: This is notice, in accordance

with 35 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(i), that the National